QYQian Yu

Qian Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qian Yu has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Osman Ahmed

    Department of Radiology, University of Chicago Medical Center, University of Chicago, Chicago, IL, 60637, USA

    19 shared publications
  • Brian Funaki

    Department of Radiology, University of Chicago Medical Center, University of Chicago, Chicago, IL, 60637, USA

    14 shared publications
  • Thuong Van Ha

    Department of Radiology, University of Chicago Medical Center, University of Chicago, Chicago, IL, 60637, USA

    13 shared publications
  • Mikin Patel

    Vascular and Interventional Radiology, University of Chicago Medical Center, University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637

    12 shared publications
  • Ethan Ungchusri

    Department of Radiology, University of Chicago Medical Center, University of Chicago, Chicago, Illinois, 60637

    10 shared publications
  • Osman Ahmed

    Joint and Vascular Institute, Libertyville, Illinois; Department of Radiology, Division of Interventional Radiology, University of Utah, Salt Lake City, Utah

    10 shared publications

Latest Publications

  • Open Access

    Radioembolization for Colorectal Liver Metastases: Indications and Outcomes

    by Sai Reddy, Xiao Wu, Natasha Rodwell, Abdul Khan, Rakesh Navuluri, Virginia Shaffer, Nicholas Fidelman, Qian Yu

    Colorectal cancer remains a leading cause of cancer-related mortality, with the liver representing the predominant site of metastatic spread. For patients with colorectal liver metastases (CRLM) who are not candidates for surgical resection, systemic chemotherapy provides disease control but rarely achieves durable hepatic responses. Radioembolization with yttrium-90 (Y-90) microspheres, delivered via the hepatic artery to exploit the preferential arterial supply of liver tumors, has emerged as an important locoregional option in this setting. This review examines the current evidence base for radioembolization in CRLM, covering patient selection, indications across lines of therapy, dosimetric advances, and clinical outcomes. Appropriate candidacy requires careful assessment of performance status, hepatic tumor burden, tumor biology, lung shunt fraction, and extrahepatic disease extent, with the strongest outcomes observed in patients selected earlier in their disease course. Randomized controlled trials support second-line and third-line use, while unselected first-line use has not demonstrated a benefit. Dosimetric advances, including multicompartment personalized dosing, radiation segmentectomy, and radiation lobectomy, are enabling ablative and bridge-to-resection strategies in appropriately selected patients. Future investigation should prioritize biomarker-driven patient selection, personalized dosimetry, and combination strategies with systemic therapy to determine whether durable hepatic disease control can translate into a survival benefit.

  • Open Access

    Intrahepatic cholangiocarcinoma treated with glass yttrium-90 radioembolization: A histopathologic study

    by Qian Yu, Peizi Li, Satvik Jain, Abdul Khan, Joseph Steiner, Chih-Yi Liao, Joseph Franses, Anjana Pillai, John Fung, J Michael Millis, et al.

    Purpose: To determine the degree of tumor necrosis on pathology and clinical outcomes among intrahepatic cholangiocarcinoma (iCCA) patients who were treated with transarterial radioembolization (TARE) and the bridge or downstaged to surgery. Methods: A single center retrospective review was performed to include consecutive patients who underwent TARE using glass microspheres and then subsequently underwent surgical resection or transplant. Baseline characteristics, dosimetry, radiologic response, histological tumor necrosis, and overall survival were evaluated. A total of 20 patients (F: M = 14:6; age: 57.3 ± 10.8 years) underwent TARE and then received resection ( n = 15) or living-donor liver transplant ( n = 5). A total of 23 selective TARE (two segments or less) were delivered, with a mean dose 301.7 ± 177.5, whereas 18 lobar (left or right hepatic artery) doses were delivered, with a mean dose of 150.3 ± 44.1 Gy. Concurrent systemic therapy was administered in 15 patients. Results: The mean time from the initial TARE to surgery was 7.1 ± 9.2 months. On pathology, complete tumor necrosis, > 90% necrosis, and extensive tumor necrosis (> 50%) were achieved in 1 (5.0%), 13 (65.0%), and 18 (90.0%) patients, respectively. The median survival time (MST) calculated from the time of surgery was 40.2 (95%CI: 15.3-not reached) months, with a 1-yr, 3-yr, and 5-yr OS of 88.2% (95CI: 60.6–96.9%), 57.8% (95%CI: 31.1–77.3%), and 19.8% (95%CI: 1.5–53.5%). From the time of initial TARE, the MST was 41.4 (95%CI:22.9-not reached) month, with a 1-yr, 3-yr, and 5-yr OS of 100%, 69.9% (95%CI: 42.0-86.3%), and 30.9% (95%CI: 9.1–56.3%). Whether the patient received concomitant systemic treatment was associated with extensive tumor necrosis on pathology (Odds Ratio: 16.0, 95%CI: 1.27-200.92, p = 0.032). Conclusion: Based on tumor explant data, TARE can result in substantial tumor necrosis in the treatment of iCCA, although complete necrosis is uncommon. The addition of systemic therapy appears to be associated with a higher likelihood of achieving extensive tumor necrosis.


  • Radiation Segmentectomy versus Combined Chemoembolization plus Microwave Ablation: Histopathologic Tumor Necrosis in Hepatocellular Carcinoma Measuring up to 5 cm

    by Qian Yu, Patrick Tran, Tanner Storozuk, Joseph Steiner, Ethan Ungchusri, Yating Wang, Rakesh Navuluri, Steven Zangan, J.MIchael Millis, John Hart, et al.


  • Transcatheter CT Hepatic Arteriography versus Conventional CT Guidance for Percutaneous Microwave Ablation of Small Hepatocellular Carcinoma Tumors

    by Qian Yu, Zaynab Ahmed, Wesley Lim, Gloria Hwang, Michael Zhang, Daniel Kwak, Chuanhong Liao, Mikin Patel, Chih-Yi Liao, Anjana Pillai, et al.

    Transcatheter CT hepatic arteriography–guided microwave ablation of small (<3 cm) hepatocellular carcinoma tumors resulted in higher initial response and progression-free survival rates than conventional CT-guided microwave ablation.

  • Occult Hepatic Artery Infusion Pump Anastomosis Leak Treated with Stent

    by Qian Yu, Jonathan Lorenz, Amith Rao, Rakesh Navuluri, Brian Funaki, Abdul Khan

  • Radiation segmentectomy for treatment of hepatic oligometastases greater than 3 cm

    by Qian Yu, Ali Ahmed, Wali Badar, Daniel Kwak, Aaron William Lyon, Yating Wang, Carla Harmath, Mikin Patel, Divya Kumari, Thuong Van Ha, et al.


  • Open Access

    Transhepatic access closure for islet cell transplant in anticoagulated patients: a comparison of microfibrillar collagen paste, coils, and coil plus gel foam

    by Qian Yu, Patrick Tran, Ethan Ungchusri, Kunal Karani, Abdul Khan, Mikin Patel, Osman Ahmed, Thuong Van Ha, Jonathan Lorenz, Steven Zangan, et al.

    Purpose: To evaluate the safety and effectiveness of microfibrillar collagen paste (MCP), coils, and coils combined with gelatin sponge for transhepatic access tract embolization following portal vein islet cell transplant. Methods: A retrospective review was conducted at a single institution between January 2008 and October 2024, including 20, 28, and 21 consecutive islet cell transplant procedures requiring transhepatic access embolization with MCP, coils, and coil plus gelatin sponge, respectively. All procedures were performed via a right portal vein branch. MCP was performed using Avitene (BD). The average number of coils required in the coil plus gelatin sponge and coil-only groups were 1.8 and 1.6 coils per procedure, respectively. All patients were placed on therapeutic anticoagulation during the procedure and for at least two weeks post-transplant. Medical records were reviewed to compare laboratory results, portal venous pressures, post-procedure liver ultrasounds, and 30-day hemorrhagic events across the three groups. Results: All procedures were technically successful. However, one instance of coil migration into a portal vein branch occurred in the coil plus gelatin sponge group (1/28, 3.5%). Baseline hemoglobin, platelet counts, and partial thromboplastin time did not differ significantly between groups ( p > 0.05). A statistically significant lower international normalized ratio (INR) was observed in the MCP group compared to the gelatin sponge and coil-only groups (1.0 vs. 1.1 vs. 1.1, p = 0.0036 and 0.004). No statistically significant differences were found in hemoglobin changes, post-transplant portal venous pressures, or post-embolization hemorrhagic events ( p > 0.05). One patient in the coil plus gelatin sponge group developed a large subcapsular hematoma (1/27, 3.7%), while another in the MCP group experienced a large right hemothorax (1/20, 5.0%). Conclusion: MCP, coils, and coil plus gelatin sponge are similarly effective for transhepatic access closure following islet cell transplant in anticoagulated patients. However, coil embolization may require multiple coils and carries a risk of migration.


  • Open Access

    Dethroning of Neuroendocrine Tumor as an Orphan Disease: US Incidence, Prevalence, and Survival in the 21st Century

    by Qian Yu, Fan Cao, Peter Hosein, Bin Huang, Paulo S. Pinheiro, Yating Wang, Jaydira Del Rivero, Gilberto Lopes, Aman Chauhan

    Importance: Neuroendocrine tumors (NETs) have traditionally been considered rare (orphan) diseases; however, improvements in diagnostic methods and heightened awareness about NETs may have altered their epidemiologic profile in the U.S. Objective: To evaluate trends in incidence, prevalence, and survival of NETs in the United States from 2000 to 2021 using updated data from the SEER-22 registry. Method: This population-based, retrospective cohort study used the SEER-22 database for incidence, prevalence, and survival analyses. Data included 231,659 patients diagnosed with NETs between 2000 and 2021. Age-adjusted incidence, limited-duration prevalence, 5-year overall survival (OS), and hazard ratios (HRs) for survival by grade, stage, year of diagnosis, race, and primary site were investigated. Results: From 2000 to 2021, NET incidence nearly doubled, from 4.6 to 8.2 per 100,000 persons. The prevalence in 2021 reached 0.064%, with grade 1 tumors showing the steepest increase. Five-year OS was 77.4% overall and highest among localized NETs (82.3%) and grade 1 tumors (80.0%). Multivariable analysis showed improved survival over time (HR for 2015–2021 vs. 2000–2004, 0.92; 95% CI, 0.89–0.95). Black and American Indian/Alaska Native patients had significantly worse outcomes than White patients. Conclusions and Relevance: NETs are no longer orphan diseases based on current U.S. incidence and prevalence trends. With increasing survival and patient numbers, there is an urgent need for expanded multidisciplinary NET care and research efforts focused on survivorship and quality of life.